What happened, in summary

This patient had multifocal lung cancer and glioma linked to a rare EGFR extracellular-domain mutation called R252C. The clinical story is mainly a molecularly guided treatment story rather than a conventional staging narrative. EGFR testing usually focuses on better-known changes inside the cell, but this case centered on a mutation outside the cell that still appeared to drive cancer growth. The R252C change substitutes cysteine for arginine at position 252. In the tumor model described with this patient's cancer, that change promoted abnormal EGFR dimerization and altered receptor shape.

The mutation behaved differently from many classic EGFR mutations. Instead of relying only on the usual EGFR autophosphorylation pathway, EGFR R252C strengthened direct interaction with ERK1/2. The altered receptor then helped activate ERK1/2 at T202/Y204, a growth-signaling step that can promote tumor-cell proliferation. This made the molecular finding especially important for treatment planning, because not every EGFR inhibitor is expected to work the same way against uncommon EGFR variants.

Afatinib, a second-generation EGFR tyrosine kinase inhibitor, was used as targeted therapy against this uncommon EGFR biology. In this case, afatinib effectively suppressed primary tumor growth and extended progression-free survival in the setting of multifocal lung cancer and glioma driven by EGFR R252C. The case highlights the value of detailed molecular profiling when cancer behaves in an unusual way or involves rare EGFR biology. For this patient, the key treatment insight was not simply that EGFR was altered, but that this specific extracellular R252C mutation pointed toward a targeted therapy option with meaningful disease control.